Venture capital co-creation: The next big thing in biotech investment?

Beyond Biotech - the podcast from Labiotech

Beyond Biotech - the podcast from Labiotech

Player FM - Internet Radio Done Right

تمت الإضافة منذ قبل three أعوام

المحتوى المقدم من Labiotech. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Labiotech أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

Uncuffed

1
S4, E1 - Day One 7:38

منذ 5 weeks7:38

التشغيل لاحقا

قوائم

إعجاب

احب

7:38

Last summer, something monumental happened. One of Uncuffed's founding producers, Greg Eskridge, came home after more than 30 years in prison. In this episode we’ll bring you back to that emotional day last summer when he walked out of the San Quentin gates, free at last. Our work in prisons is supported by the California Arts Council, the California Department of Corrections and Rehabilitation, independent foundations, and donations from listeners like you. Learn more, sign up for Uncuffed news, and support the program at www.weareuncuffed.org Follow us @WeAreUncuffed on Instagram and Facebook Transcripts are available within a week of the episode coming out at www.kalw.org/podcast/uncuffed…

منذ عام واحد 37:22

MP3•منزل الحلقة

Jessica Owens and Iana Dimkova are co-founders of Initiate Ventures—a female-led venture capital firm and studio that launched recently with a $45 million debut fund.

Initiate Ventures is shaking up the traditional venture capital model by blending investments in healthcare, life sciences, and technology with a company creation platform. The company is tackling some of the most pressing challenges in healthcare, and their innovative approach offers fresh insights into what it takes to scale transformative startups.

Owens was the co-founder of GRAIL (acquired by Illumina for $8bn) and was a partner at Kleiner Perkins, where she helped shape some of the most successful health tech startups. Dimkova is a former healthcare technology investor at GE Ventures, who also scaled a company that raised more than $700m and built one of the largest radiation therapy networks in the US.

Their approach is reflected in their dual model: funding existing companies while also co-creating ventures alongside founders in their startup studio. They helped launch groundbreaking companies like Macro Trials, a precision clinical research platform, and Persana, a leader in oncology diagnostics.

This week on the podcast, we have a conversation with one of the co-founders of the company, Jessica Owens.

00:40-05:19: About Initiate Ventures
05:19-08:33: What sets Initiate Ventures apart from other venture funds?
08:33-10:59: Revitalizing healthcare
10:59-13:46: Determining realistic company visions
13:46-15:15: Initiate Ventures and Initiate Studios
15:15-19:50: Working with companies
19:50-21:36: Working with new companies
21:36-23:00: Evaluating potential success
23:00-24:40: How hands on is Initiate Ventures?
24:40-28:24: Is there a change in what attracts capital?
28:24-30:02: Infectious disease – a neglected area
30:02-33:08: How important are ESG considerations?
33:08-35:42: Trends for 2025
35:42-36:42: Goals for 2025

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

فصول

1. Venture capital co-creation: The next big thing in biotech investment? (00:00:00)

2. About Initiate Ventures (00:00:40)

3. What sets Initiate Ventures apart from other venture funds?  (00:05:19)

4. Revitalizing healthcare  (00:08:33)

5. Determining realistic company visions  (00:10:59)

6. Initiate Ventures and Initiate Studios  (00:13:46)

7. Working with companies  (00:15:15)

8. Working with new companies  (00:19:50)

9. valuating potential success  (00:21:36)

10. How hands on is Initiate Ventures?  (00:23:00)

11. Is there a change in what attracts capital?  (00:24:40)

12. Infectious disease – a neglected area  (00:28:24)

13. How important are ESG considerations?  (00:30:02)

14. Trends for 2025  (00:33:08)

15. Goals for 2025 (00:35:42)

137 حلقات

#News #Tech News #Labiotech

Beyond Biotech - the podcast from Labiotech

Venture capital co-creation: The next big thing in biotech investment?

Beyond Biotech - the podcast from Labiotech

published منذ عام واحد

MP3•منزل الحلقة

Jessica Owens and Iana Dimkova are co-founders of Initiate Ventures—a female-led venture capital firm and studio that launched recently with a $45 million debut fund.

This week on the podcast, we have a conversation with one of the co-founders of the company, Jessica Owens.

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

فصول

1. Venture capital co-creation: The next big thing in biotech investment? (00:00:00)

2. About Initiate Ventures (00:00:40)

3. What sets Initiate Ventures apart from other venture funds?  (00:05:19)

4. Revitalizing healthcare  (00:08:33)

5. Determining realistic company visions  (00:10:59)

6. Initiate Ventures and Initiate Studios  (00:13:46)

7. Working with companies  (00:15:15)

8. Working with new companies  (00:19:50)

9. valuating potential success  (00:21:36)

10. How hands on is Initiate Ventures?  (00:23:00)

11. Is there a change in what attracts capital?  (00:24:40)

12. Infectious disease – a neglected area  (00:28:24)

13. How important are ESG considerations?  (00:30:02)

14. Trends for 2025  (00:33:08)

15. Goals for 2025 (00:35:42)

137 حلقات

#News #Tech News #Labiotech

كل الحلقات

Beyond Biotech - the podcast from Labiotech

1
The TCR-T cell therapies of tomorrow 26:42

منذ 5 أيام26:42

26:42

Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1. The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a leading Swedish industrialist, who became co-founder, and provided the initial financing. The company has raised more than €100m to date. On the podcast this week, we have a conversation with Jarvis about TCR-T cell therapies, creating off-the-shelf products and partnerships with EmendoBio and Shinobi Therapeutics. 00:43-02:10: About Anocca 02:10-04:16: About TCR-T cell therapies and their use in treatments 04:16-06:02: Anocca’s approach to T-cell biology, cutting-edge biotechnologies and integrated software 06:02-07:58: A different approach to other cell and gene therapy companies 07:58-09:16: Facing challenges 09:16-10:48: Addressing conditions and diseases 10:48-11:54: Pancreatic cancer 11:54-13:40: What represents success for Anocca? 13:40-14:09: What is VIDAR-1? 14:09-16:08: Partnerships 16:08-18:05: Scaling up and addressing costs 18:05-20:07: How is TCR-T therapy evolving? 20:07-23:11: The impact of artificial intelligence 23:11-25:16: Anocca timeline 25:16-25:57: Closing comments ` Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Can RNA drugs solve the obesity epidemic? 29:56

منذ 12 يومًا29:56

29:56

Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment. Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets underlying biological pathways to promote sustainable weight loss. By enhancing energy expenditure through white-to-brown adipose tissue conversion while preserving muscle mass, RES-010 is positioned as an ideal standalone therapy or a synergistic option for long-term weight management. The company recently initiated a phase 1 study in December 2024 for RES-010 in healthy and obese subjects, and they also secured an equity investment from Sanofi in October 2024. To talk about ways to tackle obesity, and Resalis’ approach, our guest on the podcast this week is Alessandro Toniolo, CEO of Resalis Therapeutics. 00:57-05:06: About Resalis Therapeutics 05:06-08:59: Issues of obesity 08:59-13:20: Companies working on obesity treatments 13:20-15:34: Does suppressing appetite affect nutrition? 15:34-17:49: Introduction of new obesity treatments 17:49-21:33: Approaches other than appetite suppression 21:33-22:38: RES-010 mode of action 22:38-24:04: Administration methods 24:04-25:11: Clinical trials 25:11-26:38: Resalis’ pipeline 26:38-28:08: Next steps for Resalis 28:08-28:36: Effect of obesity on other parts of the body 28:36-29:06: Final comments ` Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Reversing cancer mechanisms to fight back against solid tumors 21:24

منذ 19 يومًا21:24

21:24

CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications. Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance. Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by reenabling immune cell activation, proliferation and Interferon-γ signature induction. Visugromab has demonstrated a good safety profile and potent and durable anti-tumor efficacy in combination with anti-PD-1 treatment in advanced cancer patients, as highlighted in its recent Nature publication and interim clinical data. This week we have a conversation with Eugen Leo, chief medical officer at CatalYm. 01:30-03:38: About CatalYm 03:38-06:59: Solid tumors and also why they are hard to treat 06:59-09:04: Current treatments for solid tumors 09:04-10:47: What is immunotherapy resistance? 10:47-12:23: What is visugromab? 12:23-13:32: CatalYm’s clinical development program 13:32-15:12: What represents success for patients using visugromab? 15:12-17:50: Other treatment options being developed 17:50-19:50: CatalYm’s pipeline and the future This week’s podcast was sponsored by TCR Solutions . Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Targeting the dark genome to develop new therapies to fight obesity 32:32

منذ 26 يومًا32:32

32:32

In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity. The company’s lead candidate, HTX-001, is making progress towards the clinic in cardiomyopathy. CEO Samir is one of the first researchers to publish on lncRNA – which is also known as the Dark Genome This week, our podcast guest is Samir Ounzain, CEO and co-founder of Haya Therapeutics. Ounzain was one of the first researchers to publish on lncRNA, also known as the ‘dark genome.’ 00:55-03:47: About Haya Therapeutics 03:47-06:37: What is the dark genome? 06:37-09:29: What is the connection between lncRNA and disease? 09:30-13:22: How can disease be addressed via the dark genome? 13:22-16:45: Which diseases are you tackling? 16:45-18:02: What is the EchoHAYA platform? 18:02-21:07: How does your lead candidate, HTX-001, work? 21:07-22:00: Is the objective stopping fibrosis or reversing it? 22:00-23:41: Other companies in the field 23:41-24:52: Working with Eli Lilly 24:52-27:15: A new frontier in medicine? 27:15-28:43: Cost effectiveness 28:43-30:07: Clinical trials 30:07-31:48: Applications to other diseases Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Can Tumor Activated Therapy kill solid tumors? 31:22

منذ 5 weeks31:22

31:22

Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy. By targeting specific proteins common in all solid tumor micro-environments, Seekyo scientists think this can induce self-destruction of the tumor itself. Seekyo’s lead therapy, SKY01, can only be activated within the tumor, making it a highly-targeted solution. This differentiated approach overcomes the limits of existing treatments, such as small molecule or antibody-drug conjugates. It could also be more cost effective than many advanced, far cell and gene therapy alternatives. Seekyo is looking for clinical entry to target four of the more challenging solid cancers - pancreas, TNBC, colorectal and lung, in an umbrella PhI/IIa. This will demonstrate safety and initial efficacy readings whilst at the same time defining the lead indication to progress to later-stage development. This week, our guest is Seekyo Therapeutics’ CEO, Oury Chetboun. 00:38-01:57: About Seekyo Therapeutics 01:57-03:17: The challenges of treating solid tumors 03:17-06:08: What is Tumor Activated Therapy? 06:08-07:46: What is SKY01? 07:46-08:10: What happens to the cancer cells? 08:10-09:52: Does the tumor vanish? 09:52-10:16: How is it delivered? 10:16-11:30: Are other companies working on tumor-activated therapies? 11:30-13:09: What treatment options are being worked on for solid tumors? 13:09-13:47: Long-lasting treatment 13:47-15:33: Clinical trials 15:33-16:22: Timelines 16:22-18:08: Does the treatment have other potential applications? 18:08-19:59: Cost effectiveness 19:59-21:59: Is the goal to cure people? 21:59-22:46: Treatment frequency 22:46-24:00: The impact of tumor size 24:00-25:23: Seekyo Therapeutics’ pipeline 25:23-27:27: Fund-raising 27:27-30:33: Reaction to the therapy Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
J.P. Morgan Annual Healthcare Conference 2025: trends and highlights you may have missed 19:57

منذ 6 weeks19:57

19:57

This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently. While there weren’t necessarily many financial blockbusters, there were plenty of announcements and discussions on everything from artificial intelligence to the rising influence of Chinese companies and research, to the potential ramifications of the incoming Trump administration in the U.S. To help us navigate some of the highlights of the event, we spoke with Orca Bio’s co-founder and CEO, Ivan Dimov, and also Parabilis Medicines’ chief business officer, Greg Miller. 02:01-03:53: About Orca Bio 03:53-05:43: JPM highlights 05:43-07:26: Stand-out deals and announcements 07:26-09:01: Were any sectors more prominent than others? 09:01-12:38: About Parabilis Medicines 12:38-13:58: JPM highlights 13:58-16:33: Stand-out deals and announcements 16:33-17:53: Were any sectors more prominent than others? 17:53-19:17: Was there an optimistic mood? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Venture capital co-creation: The next big thing in biotech investment? 37:22

منذ 7 weeks37:22

37:22

Jessica Owens and Iana Dimkova are co-founders of Initiate Ventures—a female-led venture capital firm and studio that launched recently with a $45 million debut fund. Initiate Ventures is shaking up the traditional venture capital model by blending investments in healthcare, life sciences, and technology with a company creation platform. The company is tackling some of the most pressing challenges in healthcare, and their innovative approach offers fresh insights into what it takes to scale transformative startups. Owens was the co-founder of GRAIL (acquired by Illumina for $8bn) and was a partner at Kleiner Perkins, where she helped shape some of the most successful health tech startups. Dimkova is a former healthcare technology investor at GE Ventures, who also scaled a company that raised more than $700m and built one of the largest radiation therapy networks in the US. Their approach is reflected in their dual model: funding existing companies while also co-creating ventures alongside founders in their startup studio. They helped launch groundbreaking companies like Macro Trials, a precision clinical research platform, and Persana, a leader in oncology diagnostics. This week on the podcast, we have a conversation with one of the co-founders of the company, Jessica Owens. 00:40-05:19: About Initiate Ventures 05:19-08:33: What sets Initiate Ventures apart from other venture funds? 08:33-10:59: Revitalizing healthcare 10:59-13:46: Determining realistic company visions 13:46-15:15: Initiate Ventures and Initiate Studios 15:15-19:50: Working with companies 19:50-21:36: Working with new companies 21:36-23:00: Evaluating potential success 23:00-24:40: How hands on is Initiate Ventures? 24:40-28:24: Is there a change in what attracts capital? 28:24-30:02: Infectious disease – a neglected area 30:02-33:08: How important are ESG considerations? 33:08-35:42: Trends for 2025 35:42-36:42: Goals for 2025 Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Developing non-opioid pain drugs 33:01

منذ 8 weeks33:01

33:01

Brixton Biosciences, a clinical-stage life sciences company spun out from Massachusetts General Brigham, has been awarded $2m from the NIH HEAL Initiative to support the development of non-opioid, injectable pain relief solutions. As part of the NIH's efforts to tackle the U.S. opioid crisis, the funding will advance research into safer, drug-free alternatives to opioid pain management. Brixton’s Neural Ice is an injectable, drug-free pain management technology designed to provide long-lasting relief from chronic and post-operative pain. On the podcast this week, we have a conversation with Sameer Sabir, CEO and co-founder of Brixton Biosciences, to dive deeper into pain treatment, the opioid crisis, and Brixton’s mission. 01:05-02:47: About Brixton Biosciences 02:47-03:39: Brixton’s pipeline 03:39-07:46: The opioid crisis 07:46-08:41: The extent of the crisis 08:41-12:00: Current alternatives to opioids 12:00-12:40: Managing pain 12:40-17:19: How was Neural ice developed? 17:19-18:33: Duration of treatment 18:33-21:01: Suitability for different levels of pain 21:01-21:31: Speed of effect 21:31-22:37: Side effects 22:37-24:18: Opioids vs. non-opioids 24:18-25:33: Are there different responses to Neural Ice? 25:33-26:29: Standardized doses 26:29-27:42: Pricing 27:42-28:49: Other work on alternatives to opioids 28:49-30:45: Challenges to developing new pain treatments 30:45-31:57: Other priorities at Brixton 31:57-32:16: Timeline for Neural Ice Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
[Rebroadcast] The power of natural killer cells 28:59

منذ 10 weeks28:59

28:59

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season! On this podcast , we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August 2023, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease. AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva is investigating AlloNK in a phase 1/2 multicenter clinical trial to assess the safety and clinical activity of AlloNK alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL). Artiva is also investigating the safety and clinical activity of AlloNK in combination with rituximab in patients with lupus nephritis. In addition, Artiva is collaborating with Affimed in a phase 2, open-label, multi-center, multi-cohort study, testing a combination therapy, comprised of AlloNK and the innate cell engager AFM13, for the treatment of patients with relapsed/refractory CD30-positive lymphomas. Artiva selects cord blood units with the high affinity variant of the CD16 receptor and a KIR-B haplotype for enhanced product activity. Using the company’s cell therapy manufacturing platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering. AlloNK is being administered in the outpatient setting over multiple doses and multiple cycles. Artiva’s pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates targeting both solid and hematopoietic cancers. Artiva has also entered into therapeutic NK cell collaborations with Merck Sharp & Dohme. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Looking at 2025 biotech trends with SoftBank Vision Fund 39:04

منذ 11 weeks39:04

39:04

Our guest on the podcast this week is John Cassidy, director of life sciences and healthtech investments at SoftBank Vision Fund. Softbank Vision Fund is the world’s largest technology-focused investment fund, with $166bn assets under management, and a portfolio of more than 250 companies. In the discussion, we cover investment trends within life sciences, the European health and biotech scene, as well as the precise applications of new and emerging AI technologies. We also look ahead to what the biotech and life sciences fields may hold in 2025. 00:55-02:03: About the SoftBank Vision Fund 02:03-02:47: Developing timelines 02:47-04:27: Managing a large portfolio 04:27-11:18: Portfolio company profiles 11:18-13:36: Investment criteria 13:36-17:06: Trends in funding 17:06-19:09: Effects of the US election 19:09-21:45: How can companies reduce risk and raise funds? 21:45-25:25: What sectors are attracting interest currently? 25:25-27:49: Focusing on patients not profits 27:49-29:53: The impact of AI 29:53-31:45: Focus on applications 31:45-35:24: Trends in European biotech funding 35:24-38:19: Trends for 2025 Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Finding new treatments for peanut allergy 31:06

منذ 12 weeks31:06

31:06

There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens. IgGenix, a clinical-stage immunology biotechnology company, recently announced the first patient dosed in its phase 1 trial evaluating IGNX001, a novel monoclonal antibody-based therapeutic, for peanut allergy. Designed to neutralize the most clinically important peanut allergens and epitopes, IGNX001 combats peanut allergies by blocking the allergic cascade and reducing risk of anaphylaxis. Should IGNX001 prove successful, it will provide a promising solution for peanut allergies and pave the way for IgGenix's technology to be applied to other types of food allergies and allergic diseases. Our guest on the podcast this week is Jessica Grossman, chief executive officer of IgGenix. 01:14-02:51: About IgGenix 02:51-06:30: About peanut allergy 06:30-07:31: Are allergies on the rise? 07:31-08:46: Are allergy responses similar? 08:46-10:13: The problems with treating allergies 10:13-13:53: Current treatments for peanut allergy 13:53-15:45: The challenges of developing drugs to treat allergies 15:45-16:54: Overcoming the placebo effect 16:54-18:18: Are other companies working on allergy treatments? 18:18-21:32: IgGenix’s SEQ SIFTER platform 21:32-24:20: About IgGenix’s IGNX001 24:20-24:42: Repeat doses 24:42-26:19: Could peanut allergy sufferers eat peanuts? 26:19-27:46: Can the technology be adapted to treat other allergies? 27:46-28:56: Are there variations in the treatment of different allergies? 28:56-29:35: Treatments for other diseases 29:35-30:23: The future for people with allergies Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Cracking the code of biotech valuations 37:43

منذ 13 weeks37:43

37:43

ambiom is a life science commercial-advisory business development company based in the Slovakian capital of Bratislava. The company helps its corporate clients with their product strategy, in- and out-licensing efforts, including asset valuation (NPV, rNPV), M&A scouting, complex due diligence and dealmaking. ambiom also provides input on regulatory matters, support in pricing and reimbursement decisions and communication with decision-making authorities. The company guides products from the beginning - the basic science - all the way to commercialization or spin-offs. Our guest on the podcast this week is the founder and CEO of ambiom, Adam Marťák. We discuss the biotech scene in eastern Europe, the company, and look at some of the challenges facing biotech companies as they navigate the financial pathway alongside drug discovery, regulations, and commercialization. 00:45-02:33: About ambiom 02:33-03:11: ambiom clients 03:11-04:21: Biotech in eastern Europe 04:21-11:35: Focusing on a niche 11:35-13:13: What do startups need? 13:13-15:19: How do you help startups? 15:19-16:52: Tech transfer 16:52-18:35: Early-stage and late-stage biotech valuations 18:35-21:48: Different valuation methods 21:48-22:53: Why do early-stage biotech valuations offer higher upside potential for investors? 22:53-23:42: How do you measure the value of pipeline potential? 23:42-24:35: Does a bigger pipeline guarantee more success? 24:35-27:08: Can companies look more attractive to investors? 27:08-28:41: Does pipeline speed affect investment? 28:41-30:27: Which valuation method is better for biotech companies? 30:27-31:46: Are some areas of biotech better for valuations? 31:46-33:18: What affects valuation? 33:18-35:13: The difference between financing of expensive and cheaper drugs 35:13-36:57 : Is funding more difficult now, and is it changing? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Can biotech beat mosquito-borne diseases? 35:59

منذ 14 weeks35:59

35:59

Biological control company Oxitec recently launched Sparks, a new platform designed to rapidly scale Wolbachia replacement technology to take on dengue fever. Backed by a multi-million-dollar investment from the Gates Foundation, Sparks adds to Oxitec’s Aedes aegypti technology, called Friendly, which is taking on dengue fever in Brazil. With mosquito-borne diseases on the rise, Oxitec’s Friendly mosquitoes are designed to suppress populations of disease-spreading mosquitoes and, in turn, reduce biting and the threat of disease transmission. Wolbachia-carrying mosquitoes are designed to spread Wolbachia bacteria into the local mosquito population to limit the ability of the remaining infected mosquito population to transmit dengue. The platforms are designed for specific settings and intervention types, and provide options for governments and communities seeking suppression, replacement or hybrid approaches using both. Our guest on the podcast this week is the CEO of Oxitec, Grey Frandsen. 00:56-02:12: About Oxitec 02:12-05:54: The state of mosquito-borne diseases 05:54-07:09: The effect of climate change 07:09-08:29: Moving into more developed countries 08:29-10:27: Wolbachia replacement technology 10:27-12:53: The Sparks program 12:53-13:46: Other companies’ approaches 13:46-15:00: World Mosquito Program 15:00-15:30: Establishing timelines 15:30-17:20: The effect on the environment 17:20-18:54: Could adaptation render the technology useless? 18:54-20:52: Are the Sparks and Friendly programs being used together? 20:52-21:57: Do the technologies work differently on different species? 21:57-26:28: How to determine rollout conditions 26:28-27:19: Are repeat interventions needed? 27:19-30:32: Are there limitations based on cost or politics? 30:32-33:11: Are the technologies applicable to other problems? 33:11-35:08: Is there anything else in Oxitec’s pipeline? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Could antigen modulation address autoimmune diseases? 24:04

منذ 15 weeks24:04

24:04

Immunology is a key area in biotech and biopharma, both in terms of R&D and sales. However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle. To have an immunological effect, you must activate the body’s T cells, which cells requires a chain of three key signals. The first is antigen recognition, i.e. the initial detection of a cell by a T-cell. The second is the co-stimulation of non-antigen presenting molecules, which enhances the immune response. The final step is cytokine-mediated differentiation and expansion, which guides how T-cells target threats. Companies have focused on the second two signals, with signal 2 most commonly seen in therapies such as checkpoint inhibitors and monoclonal antibodies. Signal 3, on the other hand, can be primarily seen in therapies for autoimmune disorders, such as anti-TNF and JAK inhibitors. Greywolf Therapeutics is the first company to explore changing signal 1. The company says focusing on signal 1 applies in three key therapeutic areas: oncology, autoimmunity and virology. Greywolf’s first candidate has delivered strong results during its ongoing phase I/II trial in oncology, therefore demonstrating proof-of-mechanism and target engagement, with its next candidate well-progressed in preclinical development in autoimmunity. To tell us more about the company and its work is Pete Joyce, CEO and co-founder of Greywolf Therapeutics. 01:19-04:12: About Greywolf Therapeutics 04:12-04:51: The origins of the name 04:51-06:52: The three ‘signals’ of the mechanics of immunological responses 06:52-08:31: Treatments associated with each signal 08:31-10:09: Why is step 1 important, and why has it not been investigated for treatments? 10:09-11:28: What areas of disease is this applicable to? 11:28-12:19: How do you inhibit ERAP? 12:19-14:01: Greywolf Therapeutics’ candidates 14:01-15:11: How is this an advance on current treatments? 15:11-16:05: What is success for patients? 16:05-17:20: How does the stage of disease affect treatment? 17:20-18:09: Are other companies looking into antigen modulation? 18:09-19:47: Has this led to investment opportunities? 19:47-21:15: Next steps 21:15-21:55: Do you anticipate more interest in this space? 21:55-23:21: Attending events Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Beyond profits: The Bill & Melinda Gates MRI's mission to combat neglected diseases 38:10

منذ 16 weeks38:10

38:10

The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoclonal antibodies to address substantial global health concerns, for which investment incentives are limited, including malaria, tuberculosis, diarrheal diseases, and diseases that impact maternal, newborn, and child health. This week, our guest is Dr Claire Wagner, head of corporate strategy and market access at Gates MRI. Wagner has dedicated her life to global health. Her early years working in West Africa and East Africa – including five years working with the Rwanda Ministry of Health – were formative experiences for her. She helped document health sector outcomes in Rwanda and had a front row seat to the progress the country was making at the time, which led to her pursuing and obtaining an MD and MBA from Harvard. Her experiences led to her becoming one of the early employees of the Gates MRI, where she is on the executive leadership team and leads the institute's global access strategy as well as related engagement with commercial partners, financial institutions and multilaterals. She tackles the challenge of paving the way for the drugs, biologics and vaccines that the Gates MRI is developing – if they are successful in clinical trials – to be affordable and accessible to the people in low- and middle-income countries who would benefit most. In March 2024 the Gates MRI launched a phase 3 clinical trial for a tuberculosis vaccine candidate, and market access for this candidate is a top priority for Wagner. 01:51-04:47: Background on Dr Claire Wagner 04:47-06:24: Work in Rwanda 06:24-08:40: Gates MRI 08:40-12:50: Progress at Gates MRI 12:50-14:06: Gates MRI R&D priorities 14:06-16:26: The differences between Gates MRI and traditional biotechs 16:26-18:40: Gates MRI partnerships 18:40-22:52: The inequality of developing drug treatments 22:52-25:45: Return on investment 25:45-27:01: Did COVID increase global awareness? 27:01-27:44: Other companies working on treatments 27:44-31:48: Gates MRI pipeline and clinical trials 31:48-34:51: Working on tuberculosis 34:51-36:00: Treatment mode of action 36:00-37:25: Future work at Gates MRI Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.

الاستماع إلى +500 موضوع

مشابه لـBeyond Biotech - the podcast from Labiotech

Amazon eGift Card - Amazon Logo (Animated)

Amazon Basics Clear Thermal Laminating Plastic Paper Laminator Sheets, 9 x 11.5-Inch, 200-Pack, 3mil

Crocs Unisex-Child Classic Clogs, Black/Black, 4 Big Kid

المدونة الصوتية تستحق الاستماع

Beyond Biotech - the podcast from Labiotech « » Venture capital co-creation: The next big thing in biotech investment?

فصول

1. Venture capital co-creation: The next big thing in biotech investment? (00:00:00)

2. About Initiate Ventures (00:00:40)

3. What sets Initiate Ventures apart from other venture funds? (00:05:19)

4. Revitalizing healthcare (00:08:33)

5. Determining realistic company visions (00:10:59)

6. Initiate Ventures and Initiate Studios (00:13:46)

7. Working with companies (00:15:15)

8. Working with new companies (00:19:50)

9. valuating potential success (00:21:36)

10. How hands on is Initiate Ventures? (00:23:00)

11. Is there a change in what attracts capital? (00:24:40)

12. Infectious disease – a neglected area (00:28:24)

13. How important are ESG considerations? (00:30:02)

14. Trends for 2025 (00:33:08)

15. Goals for 2025 (00:35:42)

Venture capital co-creation: The next big thing in biotech investment?

فصول

1. Venture capital co-creation: The next big thing in biotech investment? (00:00:00)

2. About Initiate Ventures (00:00:40)

3. What sets Initiate Ventures apart from other venture funds? (00:05:19)

4. Revitalizing healthcare (00:08:33)

5. Determining realistic company visions (00:10:59)

6. Initiate Ventures and Initiate Studios (00:13:46)

7. Working with companies (00:15:15)

8. Working with new companies (00:19:50)

9. valuating potential success (00:21:36)

10. How hands on is Initiate Ventures? (00:23:00)

11. Is there a change in what attracts capital? (00:24:40)

12. Infectious disease – a neglected area (00:28:24)

13. How important are ESG considerations? (00:30:02)

14. Trends for 2025 (00:33:08)

15. Goals for 2025 (00:35:42)

المدونة الصوتية تستحق الاستماع

مرحبًا بك في مشغل أف ام!

Goo Gone Original Liquid - 8 Ounce - Surface Safe Adhesive Remover Safely Removes Stickers Labels Decals Residue Tape Chewing Gum Grease Tar Crayon Glue

Bostitch Office Personal Electric Pencil Sharpener, Powerful Stall-Free Motor, High Capacity Shavings Tray, Blue

iBayam 2 Pack Tape Measure Measuring Tape for Body Fabric Sewing Tailor Cloth Knitting Vinyl Home Craft Measurements, 60-Inch Soft Fashion Pink & Retractable Black Double Scales Rulers for Body Weight

SHAPERMINT Shapewear for women - High-Waisted Shapewear Tummy Control Shorts, Faja body shaper, underwear for women

مشابه لـBeyond Biotech - the podcast from Labiotech

دليل مرجعي سريع

Beyond Biotech - the podcast from Labiotech « »
Venture capital co-creation: The next big thing in biotech investment?

3. What sets Initiate Ventures apart from other venture funds?  (00:05:19)

4. Revitalizing healthcare  (00:08:33)

5. Determining realistic company visions  (00:10:59)

6. Initiate Ventures and Initiate Studios  (00:13:46)

7. Working with companies  (00:15:15)

8. Working with new companies  (00:19:50)

9. valuating potential success  (00:21:36)

10. How hands on is Initiate Ventures?  (00:23:00)

11. Is there a change in what attracts capital?  (00:24:40)

12. Infectious disease – a neglected area  (00:28:24)

13. How important are ESG considerations?  (00:30:02)

14. Trends for 2025  (00:33:08)

3. What sets Initiate Ventures apart from other venture funds?  (00:05:19)

4. Revitalizing healthcare  (00:08:33)

5. Determining realistic company visions  (00:10:59)

6. Initiate Ventures and Initiate Studios  (00:13:46)

7. Working with companies  (00:15:15)

8. Working with new companies  (00:19:50)

9. valuating potential success  (00:21:36)

10. How hands on is Initiate Ventures?  (00:23:00)

11. Is there a change in what attracts capital?  (00:24:40)

12. Infectious disease – a neglected area  (00:28:24)

13. How important are ESG considerations?  (00:30:02)

14. Trends for 2025  (00:33:08)